Horizon Pharma plc and XL-protein GmbH have entered into a collaboration agreement on a potential next-generation biologic for uncontrolled gout using PASylation® technology
FREISING, January 9, 2018 /XL-protein/ — Horizon Pharma plc (NASDAQ:HZNP) yesterday announced that it has entered into a collaboration agreement with XL-protein GmbH to identify clinical-stage program candidates that could use PASylation® technology to construct a next-generation gout biologic.
PASylation® technology is a biological alternative to synthetic PEGylation and is intended to extend both the half-life of uricase and the duration of treatment for people living with uncontrolled gout, and also has the potential for subcutaneous dosing.
If the agreement yields a clinical-stage candidate, Horizon Pharma will have the right to license the candidate.
About XL-protein GmbH
XL-protein is a German biotech company commercializing its ground-breaking PASylation® technology, which enables the design of biopharmaceuticals with extended plasma half-life and enhanced action. Based on a strong proprietary technology position, XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in diverse disease areas. XL-protein is engaged in a growing number of partnerships with international pharmaceutical and biotech companies at various levels. For more information, please visit www.xl-protein.com
Download full press release